Current status of therapy in nonalcoholic fatty liver disease

Therapeutic Advances in Gastroenterology

Volumn 2, Issue 1, 2009, Pages 29-43

  McNear, Scott ^a   Harrison, Stephen A ^a  

^a BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

Ezetimibe; Gemfibrozil; HMG Co A reductase inhibitors; Metformin; Nonalcoholic fatty liver disease; Obesity; Probucol; Thiazolidinediones; Ursodeoxycholic acid

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ASCORBIC ACID; ATORVASTATIN; DIETHANOLAMINE; DIISOPROPYLAMINE DICHLOROACETATE; EXENDIN 4; FRUCTOSE OLIGOSACCHARIDE; GEMFIBROZIL; GLITAZONE DERIVATIVE; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INT 747; LOSARTAN; METFORMIN; NICOTINAMIDE; PHOSPHATIDYLCHOLINE; PIOGLITAZONE; PROBIOTIC AGENT; RESVERATROL; RIMONABANT; ROSIGLITAZONE; SIBUTRAMINE; SILIBININ; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; YOJOHENSHIKO;

CHINESE HERB; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC PROCEDURE; DIET THERAPY; DRUG MEGADOSE; EXERCISE; HUMAN; LIVER BIOPSY; MONOTHERAPY; MORBIDITY; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PATHOGENESIS; PATIENT SAFETY; PREVALENCE; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; ULTRASOUND; WEIGHT REDUCTION;

EID: 77951620302     PISSN: 1756283X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756283X08100327     Document Type: Review

References (101)

1. Abdelmalek, M., Angulo, P., Jorgensen, R., Sylvestre, P. and Lindor, K. (2001) Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study, Am J Gastroenterol 96: 2711-2717.
2. Adams, L., Zein, C., Angulo, P. and Lindor, K. (2004) A pilot trial of pentoxifylline in nonalcoholic steatohepatitis, Am J Gastroenterol 99: 2365-2368.
3. Aithal, G., Thomas, J., Kaye, P., Lawson, A., Ryder, S., Spendlove, I. et al. (2008) Randomized, placebo controlled trial of pioglitazone in non-diabetic subjects with nonalcoholic steatohepatitis (NASH), Gastroenterology 135: 1176-1184.
4. Anderson, T., Gluud, C., Franzmann, M. and Christofferen, P. (1991) Hepatic effects of dietary weight loss in morbidly obese subjects, J Hepatol 12: 224-229.
5. Angelico, F., Burattin, M., Alessandri, C., Del Ben, M. and Lirussi, F. (2007) Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis, Cochrane Database Syst. Rev. 1: CD005166.
6. Angulo, P., Hui, J., Marchesini, G., Bugianesi, E., George, J., Farrell, G. et al. (2007) The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD, Hepatology 45: 846-854.
7. Araki, T. and Kitaoka, H. (2001) Antioxidative properties of probucol estimated by the reactivity with superoxide and by electrochemical oxidation, Chem Pharm Bull 49: 943-947.
8. Arslan, U., Turkoglu, S., Balcioglu, S., Tavil, Y., Karakan, T. and Cengel, A. (2007) Association between nonalcoholic fatty liver disease and coronary artery disease, Coron Artery Dis 18: 433-436.
9. Basaranoglu, M., Acbay, O. and Sonsuz, A. (1999) A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis (letter), J Hepatol 31: 384.
10. Belfort, R., Harrison, S., Brown, K., Darland, C., Finch, J., Hardies, J. et al. (2006) A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis, N Engl J Med 355: 2297-2307.
11. Bergheim, I., Weber, S., Vos, M., Kramer, S., Volynets, V., Kaserouni, S. et al. (2008) Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin, J Hepatol 48: 983-992.
12. Browning, J., Szczepaniak, L., Dobbins, R., Nuremberg, P., Horton, J., Cohen, J. et al. (2004) Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity, Hepatology 40: 1387-1395.
13. Bugianesi, E., Gentilcore, E., Manini, R., Natale, S., Vanni, E., David, E. et al. (2005) A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease, Am J Gastroenterol 100: 1082-1090.
14. Chande, N., Laidlaw, M., Adams, P. and Marotta, P. (2006) Yo Jyo Hen Shi Ko (YHK) improves transaminases in nonalcoholic steatohepatitis (NASH): a randomized pilot study, Dig Dis Sci 51: 1183-1189.
15. Charatcharoenwitthaya, P., Levy, C., Angulo, P., Keach, J., Jorgensen, R. and Lindor, K. (2007) Open-label pilot study of folic acid in patients with nonalcoholic steatohepatitis, Liver Int 27: 220-226.
16. Craig, S.A. (2004) Betaine in human nutrition, Am J Clin Nutr 80: 539-549.
17. Das, K. and Kar, P. (2005) Update article: Non-alcoholic steatohepatitis, JAPI 53: 195-199.
18. Daubioul, C., Horsmans, Y., Lambert, P., Danse, E. and Delzenne, N. (2005) Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study, EJCN 59: 723-726.
19. Daubioul, C., Taper, H., de Wispelarera, L. and Delzenne, N. (2000) Dietary oligofructose lessens hepatic steatosis, but does not prevent hypertriglyceridemia in obese Zucker rats, J Nutr 130: 1314-1319.
20. Dehghan, M., Akhtar-Danesh, N. and Merchant, A. (2005) Childhood obesity, prevalence and prevention, Nutrit J 4: 24.
21. de Luis, D., Aller, R., Izaola, O., Sagrado, M., Conde, R., Gonzalez, J. et al. (2008) Effect of a hypocaloric diet in transaminases in nonalcoholic fatty liver disease and obese patients, relation with insulin resistance, Diabetes Res Clin Pract 79: 74-78.
22. Deushi, M., Nomura, M., Kawakami, A., Haraguchi, M., Ito, M., Okazaki, M. et al. (2007) Ezetimibe improves liver steatosis and insulin resistance in obese model of metabolic syndrome, FEBS Lett 581: 5664-5670.
23. Dixon, J., Bhathal, P. and O'Brien, P. (2006) Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement, Obes Surg 16: 1278-1286.
24. Donnelly, K., Smith, C., Schwarzenberg, S., Jessurun, J., Boldt, M. and Parks, E. (2005) Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease, J Clin Invest 115: 1139-1142.
25. Dufour, J., Oneta, C., Gonvers, J., Bihl, F., Cerny, J., Cereda, J. et al. (2006) Randomized placebo-controlled trial of ursodeoxycholic acid with vitamine E in nonalcoholic steatohepatitis, Clin Gastroenterol Hepatol 4: 1537-1543.
26. Dunn, W., Xu, R. and Schwimmer, J. (2008) Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease, Hepatology 47: 1947-1954.
27. Ebihara, K., Kusakabe, T., Hirata, M., Masuzaki, H., Miyanaga, F., Kobayahi, N. et al. (2007) Effiacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy, J Clin Endocrinol Metab 92: 532-541.
28. Ekstedt, M., Franzen, L., Mathiesen, U., Homqvist, M., Bodemar, G. and Kechagias, S. (2007) Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study, J Hepatol 47: 135-141.
29. Federico, A., Trappoliere, M., Tuccillo, C., de Sio, I., Di Leva, A., Del Vecchio Blanco, C. et al. (2006) A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations, Gut 55: 901-902.
30. Gary-Bobo, M., Elachouri, G., Gallas, J., Janiak, P., Marini, P., Ravinet-Trillou, C. et al. (2007) Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese zucker fa/fa rats, Hepatology 46: 122-129.
31. Gholam, P., Flanebaum, L., Machan, J., Charney, D. and Kutler, D. (2007) Nonalcoholic fatty liver disease in severely obese subjects, Am J Gastroenterol 102: 399-408.
32. Gomez-Dominguez, E., Gisbert, J., Moreno-Monteagudo, J., Garcia-Buey, L. and Moreno-Otero, R. (2006) A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients, Aliment Pharmacol Ther 23: 698-699.
33. Haque, M. and Sanyal, A. (2002) The metabolic abnormalities associated with nonalcoholic fatty liver disease, Best Pract Res Clin Gastroenterol 16: 709-731.
34. Harrison, S., Brunt, E. and Fecht, W. (2008) Orlistat in the treatment of overweight patients with nonalcoholic steatohepatitis (NASH): a multi-centered, randomized prospective trial, Hepatology in press.
35. Harrison, S. and Day, C. (2007) Benefits of lifestyle modification in NAFLD, Gut 56: 1760-1769.
36. Harrison, S., Oliver, D., Arnold, H., Gogia, S. and Neuschwander-Tetri, B. (2008) Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease, Gut 57: 1441-1447.
37. Harrison, S., Torgerson, S. and Hayashi, P. (2003 a) The natural history of nonalcoholic fatty liver disease: a clinical histopathological study, Am J Gastroenterol 98: 2042-2047.
38. Harrison, S., Torgerson, S., Hayashi, P., Ward, J. and Schenker, S. (2003 b) Vitamin E and vitamin C improves fibrosis in patients with nonalcoholic steatohepatitis, Am J Gastroenterol 98: 2348-2350.
39. Harrison, S. (2008) Abnormal liver tests and fatty liver on ultrasound, Clin Gastro Hepatol 6: 26-29.
40. Hirose, A., Ono, M., Saibara, T., Nozaki, Y., Masuda, K., Yoshioka, A. et al. (2007) Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis, Hepatology 45: 1375-1381.
41. Huang, M., Greenson, J., Chao, C., Anderson, L., Peterson, D., Jacobson, J. et al. (2005) One-year intesnse nutritional counseling results in histological improvement in patients with nonalcoholic steatohepatitis: a pilot study, Am J Gastroenterol 100: 1072-1081.
42. Huang, X., Fan, Y., Zhang, H., Wang, P., Yuan, J., Li, M. et al. (2008) Serum leptin and soluble leptin receptor in non-alcoholic fatty liver disease, World J Gastroenterol 14: 2888-2893.
43. Iijima, H., Moriyasu, F., Tsuchiya, K., Suzuki, S., Yoshida, M., Shimizu, M. et al. (2007) Decrease in accumulation of ultrasound contrast microbubbles in non-alcoholic steatohepatitis, Hepatol Res 37: 722-730.
44. Joy, D., Thava, V. and Scott, B. (2003) Diagnosis of fatty liver disease: is biopsy necessary ? Eur J Gastroenterol Hepatol 15: 539-543.
45. Kitamura, N., Ota, Y. and Mimura, K. (1999) Effects of diisopropylamine dichloroacetate on proliferation and differentiation of normal human keratinocytes in vitro, Skin Parmachology and Applied Skin Physiology 12: 317-325.
46. Kiyici, M., Gulten, M., Gurel, S., Nak, S., Dolar, E., Savci, G. et al. (2003) Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis, Can J Gastroenterol 17: 713-718.
47. Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C. et al. (2004) Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins, Nat Med 10: 1344-1351.
48. Le, K., Tappy, L. and D'Alessio, D. (2007) Mitochondrial dysfunction and insulin resistance: a matter of lifestyle?, Curr Opin Nutr Metab Care 10: 494-497.
49. Leevy, C. (1962) Fatty liver: A study of 270 patients with biopsy proven fatty liver and a review of the literature, Medicine 41: 249-278.
50. Lewis, J., Mortensen, M., Zweig, S., Fusco, M., Medoff, J. and Belder, R. (2007) Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial, Hepatology 46: 1453-1463.
51. Lindor, K., Kowdley, K., Heathcote, E., Harrison, M., Jorgensen, R., Angulo, P. et al. (2004) Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial, Hepatology 39: 770-778.
52. Loguercia, C., Federico, A., Tuccillo, C., Terracciano, F., D'Auria, M., de Simone, C. et al. (2005) Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver disease, J Clin Gastroenterol 39: 540-543.
53. Lu, L., Zeng, M., Mao, Y., Chen, C., Fu, Q., Wang, J., Xie, W. et al. (2005) Diisopropylamine dichloroacetate in the treatment of nonalcoholic fatty liver disease: a multicenter random double-blind controlled trial, Chinese J Hepatol 13: 92-95.
54. Lutchman, G., Promrat, K., Kleiner, D., Heller, T., Ghany, M., Yanovski, J. et al. (2006) Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis, relationship to histologic improvement, Clin Gastroenterol Hepatol 4: 1048-1052.
55. Machado, M., Marques-Vidal, P. and Cortez-Pinto, H. (2006) Hepatic histology in obese patients undergoing bariatric surgery, J Hepatol 45: 600-606.
56. Manning, D. and Afdhal, N. (2008) Diagnosis and quantitation of fibrosis, Gastroenterology 134: 1670-1681.
57. Marchensini, G., Bianchi, G., Tomassetti, S., Zoli, M. and Melchionda, N. (2001) Metformin in non-alcoholic steatohepatitis, Lancet 348: 893-894.
58. Marubbio, A., Buchwald, H., Schwartz, H. and Varco, R. (1976) Hepatic lesions of central pericellular fibrosis in morbid obesity and after jejunoileal bypass, Am J Clin Pathol 66: 684-691.
59. Mattar, S., Velcu, L., Rabinovitz, M., Krasinskas, A., Barinas-Mitchell, M., Eid, G. et al. (2005) Surgically-induced weight loss significantly improved nonalcoholic fatty liver disease and the metabolic syndrome, Ann Surg 242: 610-620.
60. Mendez-Sanchez, N., Gonzalez, V., Chavez-Tapia, N., Ramos, M. and Uribe, M. (2004) Weight reduction and ursodeoxycholic acid subjects with nonalcoholic fatty liver disease. A double-blind, placebo controlled trial, Ann Hepatol 3: 108-112.
61. Merat, S., Aduli, M., Kazemi, R., Sotoudeh, M., Sedighi, N., Sohrabi, M. et al. (2008) Liver histology changes in nonalcoholic steatohepatitis after one year of treatment with probucol, Dig Dis Sci 53: 2246-2250.
62. Merat, S., Malekzadeh, R., Sohrabi, M., Sotoudeh, M., Rakhshani, N., Sohrabpour, A. et al. (2003) Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study, J Hepatol 38: 414-418.
63. Miglio, F., Rovati, L., Santoro, A. and Setnikar, I. (2000) Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study, Arzneimittelforschung 50: 722-727.
64. Miller, E., Pastor-Barriuso, R., Dalal, D., Riemersma, R., Appel, L. and Guallar, E. (2005) Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality, Ann Intern Med 142: 37-46.
65. Mottin, C., Moretto, M., Padoin, A., Swarowsky, A., Toneto, M., Glock, L. et al. (2004) The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients, Obes Surg 14: 635-637.
66. Neuschwander-Tetri, B.A. and Bacon, B. (1996) Nonalcoholic steatohepatitis, Med Clin North Am 80: 1147-1166.
67. Ochiai, H., Ooka, H., Shida, C., Ishikawa, T., Inoue, D. and Okazaki, R. (2008) Acarbose treatment increases serum total adiponectin levels in patients with type 2 diabetes, Endocr J 55: 549-556.
68. Oral, E., Simha, V., Ruiz, E., Anderwelt, A., Premkumar, A., Snell, P. et al. (2002) Leptin-replacement therapy for lipodystrophy, N Engl J Med 346: 570-578.
69. Ouyang, X., Cirillo, P., Sautin, Y., McCall, S., Bruchette, J., Diehl, A. et al. (2008) Fructose consumption as a risk factor for nonalcoholic fatty liver disease, J Hepatol 48: 993-999.
70. Parsons, T., Power, C. and Summerbell, C. (1999) Childhood predictors of adult obesity: a systematic review, Int J Obesity 23: S1-S107.
71. Ratziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann-Heurtier, A., Serfaty, L., et al. (2008) Rosiglitazone for nonalcoholic steatohepatitis: One-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial, Gastroenterology 135: 100-110.
72. Ratziu, V., Massard, J., Charlotte, F., Imbert-Bismut, F., Bonyhay, L., Tahiri, M. et al. (2006) Diagnostic value of biochemical markers (Fibro Test-Fibro SURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease, BMC Gastroenterol 14: 6-34.
73. Rinella, M., Elias, M., Smolak, R., Fu, T., Borensztajn, J. and Green, R. (2008) Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet, J Lipid Res 49: 1068-1076.
74. Ryan, M., Abbasi, F., Lamendola, C., Carter, S. and McLaughlin, T. (2007) Serum alanine aminotransferase levels decrease further with carbohydrate than fat restriction in insulin-resistant adults, Diabetes Care 30: 1075-1080.
75. Sabuncu, T., Nazligul, Y., Karaoglanoglu, M., Ucar, E. and Kilic, F. (2003) The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis, Rom J Gastroenterol 12: 189-192.
76. Santos, V., Lanzoni, V., Szenjnfeld, J., Shigueoka, D. and Parise, R. (2003) A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid, Brazilian J Med Bio Res 36: 723-729.
77. Sanyal, A., Mofrad, P., Contos, M., Sargeant, C., Luketic, V., Sterling, R. et al. (2004) A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis, Clin Gastroenterol Hepatol 2: 1107-1115.
78. Satapathy, S., Sakhuja, P., Malhotra, V., Sharma, B. and Sarin, S. (2007) Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinlammation in patients with non-alcoholic steatohepatitis, J Gastroenterol Hepatol 22: 634-638.
79. Screenivasa Baba, C., Alexander, G., Kalyani, B., Pandey, R., Rastogi, S., Pandey, A. et al. (2006) Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis, J Gastroenterol Hepatol 21: 191-198.
80. Shang, J., Chen, L., Xiao, F., Sun, H., Ding, H. and Xiao, H. (2008) Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase, Acta Pharmacol Sin 29: 698-706.
81. Stefano, J., de Oliveira, C., Correa-Giannella, M., de Lima, V., de S'a, S., de Oliveira, E. et al. (2008) Nonalcholic steatohepatitis (NASH) in OB-OB mice treated with YHK (Yojo Henshi Ko): effects on peroxisome proliferator-activated receptors (PPARs) and microsomal triglyceride transfer protein (MTP), Med J 27: 227-234.
82. Suzuki, A., Lindor, K., St Saver, J., Lymp, J., Mendez, F., Muto, A. et al. (2005) Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease, J Hepatol 43: 1060-1066.
83. Targher, G., Bertonlini, L., Poli, F., Rodella, S., Scala, L., Tessari, R. et al. (2005) Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients, Diabetes 54: 3541-3546.
84. Thomas, E., Brynes, A., Hamilton, G., Patel, N., Spong, A., Goldin, R. et al. (2006) Effect of nutritional counseling on hepatic, muscle, and adipose fat tissue contentand distribution in nonalcoholic fatty liver disease, World J Gastroenterol 12: 5813-5819.
85. Toblli, J., Munoz, M., Cao, G., Mella, J., Pereyra, J. and Mastai, R. (2008) ACE inhibition and AT 1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats, Obesity 16: 770-776.
86. Tushuizen, M., Bunck, M., Pouwels, P., van Waesberghe, J., Diamant, M. and Heine, R. (2006) Incretin mimetics as a novel therapeutic option for hepatic steatosis, Liver Int 26: 1015-1017.
87. Uygun, A., Kadayifci, A., Isik, A., Ozgurtas, T., Deveci, S., Tuzun, A. et al. (2004) Metformin in the treatment of patients with non-alcoholic steatohepatitis, Aliment Pharmacol Ther 19: 537-544.
88. van der Poorten, D., Milner, K., Hui, J., Hodge, A., Trenell, M., Kench, J. et al. (2008) Visceral fat: A key mediator of steatohepatitis in metabolic liver disease, Hepatology 48: 449-457.
89. Wang, R. and Koretz, R. (2003) Is weight reduction an effective therapy for nonalcoholic fatty liver disease? A systematic review, Am J Med 115: 554-559.
90. Wanless, I. and Lentz, J. (1990) Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors, Hepatology 12: 1106-1110.
91. Weisberg, S., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. and Ferrant, A. (2003) Obesity is associated with macrophage accumulation in adipose tissue, J Clin Invest 112: 1796-1808.
92. Whitaker, R., Wright, J., Pepe, M., Seidel, K. and Dietz, W. (1997) Predicting obesity in young adult-hood from childhood and parental obesity, N Engl J Med 337: 869-873.
93. Wong, V., Wong, G., Chim, A., Tse, A., Tsang, S., Hui, A. et al. (2008) Validation of NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis, Am J Gastroenterol 103: 1682-1688.
94. World Health Organization (2006) Fact Sheet No. 311. WHO, Geneva.
95. Xu, A., Wang, Y., Keshaw, H., Xu, L.Y., Lam, K.S., Cooper, G.T. (2003) The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice, J Clin Invest 112: 91- 100.
96. Yakaryilmaz, F., Guliter, S., Savas, B., Erdem, O., Ersoy, R., Erden, E. et al. (2007) Effects of vitamin E treatment on peroxisome proliferator-activated receptor-[alpha] expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study, Intern Med J 37: 229-235.
97. Yokohama, S., Yoneda, M., Haneda, M., Okamoto, S., Okada, M., Aso, K. et al. (2004) Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis, Hepatology 40: 1222-1225.
98. Zelber-Sagi, S., Kessler, A., Brazowsky, A., Webb, M., Lurie, Y., Santo, M. et al. (2006) A double-blind randomized placebo controlled trial of orlistat for treatment of nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol 4: 639-644.
99. Zelber-Sagi, S., Nitzan-Kaluski, D., Goldsmith, R., Webb, M., Blendis, L., Helpern, Z. et al. (2008) Long term nutritional intake and the risk for nonalcoholic fatty liver disease (NAFLD): a population based study, J Hepatol 47: 711-717.
100. Zheng, S., Hoos, L., Cook, J., Tetzloff, G., Davis, H., van Heek, M. et al. (2008) Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice, Eur J Pharmacol 584: 118-124.
101. Zivkovic, A., German, J. and Sanyal, A. (2007) Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease, Am J Clin Nutr 86: 282-300.